Testing liothyronine with chemotherapy for medulloblastoma that came back
Original title: Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so it is still very new.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests liothyronine plus chemotherapy for medulloblastoma that came back or kept growing.
Who this trial is for. This trial is for children and young adults whose medulloblastoma came back or kept growing after their first standard treatment. It tests liothyronine given with three chemotherapy drugs, bevacizumab, irinotecan, and temozolomide.
Where it stands. The study is still checking how liothyronine works when used with this chemotherapy. The answer is not in yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: Some families look at trials when a tumor comes back. If this sounds like your situation, you can ask your care team about it. They can help you weigh it.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, August 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.